NEW YORK (GenomeWeb News) – Genetic test development firm Interleukin Genetics today announced it raised $12 million in gross proceeds through a private placement with accredited investors.

The Waltham, Mass.-based firm said its sold about 43.7 million shares of its common stock at $0.2745 per share and issued warrants to purchase an aggregate of about 32.8 million shares of common stock at an exercise price of $0.2745 per share to the investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

In Nature this week: a Danish reference genome, and more.